{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"9.5","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"sCR was assessed according to the International Myeloma Working Group (IMWG) 2006 response criteria. sCR was defined as complete response \\[CR\\] plus normal serum free light-chain ratio and absence of clonal cells in bone marrow. CR criteria are negative immunofixation of serum and urine and disappearance of soft tissue plasmacytomas and ≤5% plasma cells in the bone marrow. The percentage of participants with sCR as assessed by the investigator is presented.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle OR 10 mg/kg by IV infusion on Day 1 of each 14-day cycle.","id":"OG000","title":"Cohort 2: Relapsed Refractory/Refractory (rR/R) Multiple Myeloma (MM)"}],"paramType":"NUMBER","populationDescription":"All participants in Cohort 2 with a baseline efficacy evaluation and at least 1 post-baseline efficacy evaluation.","reportingStatus":"POSTED","timeFrame":"Up to approximately 78.5 months","title":"Stringent Complete Remission (sCR) in Cohort 2: Relapsed Refractory/Refractory (rR/R) Multiple Myeloma (MM)","type":"SECONDARY","unitOfMeasure":"Percentage of partiicpants"}